Sandbox leucocytosis: Difference between revisions
Aditya Ganti (talk | contribs) No edit summary |
No edit summary |
||
Line 458: | Line 458: | ||
{| | {| | ||
|- | |- | ||
! colspan=" | ! colspan="3" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Normal variant oral lesions | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 465: | Line 465: | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan=" | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoedema | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 472: | Line 472: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan=" | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Fordyce granules | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 479: | Line 479: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
! colspan=" | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Benign Oral lesions | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 486: | Line 486: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| colspan=" | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Pyogenic granuloma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 493: | Line 493: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan=" | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral ossifying fibroma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 500: | Line 500: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan=" | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Granular cell tumor | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 507: | Line 507: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan=" | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Peripheral giant cell granuloma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 514: | Line 514: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan=" | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral hemangioma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 521: | Line 521: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| | | rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |Benign peripheral nerve sheath tumor | ||
| colspan="2" |Traumatic neuroma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 528: | Line 529: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| colspan="2" style="background: #DCDCDC; padding: 5px; text-align: center;" | | | colspan="2" |Neurofibroma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Schwannoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" rowspan="2" |Palisaded encapsulated neuroma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Neodymium-doped yttrium alluminium garnet | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 535: | Line 563: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" | | | rowspan="11" style="background: #DCDCDC; padding: 5px; text-align: center;" |Pigmented lesions | ||
| | | rowspan="6" |Diffuse | ||
|Peutz-jeghers syndrome | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 543: | Line 572: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| | |Addison's disease | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Heavy metal | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Drug induced | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Post inflammatory | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Smoker's melanosis | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| rowspan="5" |Focal | |||
|Ephelides | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Labial melanocytic macules | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Amalgam tattoo | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Oral melanoacanthoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Oral melanocytic nevi | |||
| | |||
| | |||
| | |||
| | |||
| | | | ||
|- | |- | ||
! colspan=" | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Pre-malignant oral lesions | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 558: | Line 650: | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoplakia | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Leukoplakia | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 566: | Line 657: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral proliferative verrucous leukoplakia | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral proliferative verrucous leukoplakia | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 574: | Line 664: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Erythroplakia | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Erythroplakia | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 582: | Line 671: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral submucus fibrosis | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral submucus fibrosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 590: | Line 678: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral lichen planus and lichenoid lesions | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral lichen planus and lichenoid lesions | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 598: | Line 685: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral discoid lupus erythmatosus | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral discoid lupus erythmatosus | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 606: | Line 692: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral chronic graft vs host disease | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Oral chronic graft vs host disease | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 614: | Line 699: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Actinic chelitis | | colspan="3" style="background: #DCDCDC; padding: 5px; text-align: center;" |Actinic chelitis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 622: | Line 706: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
! colspan=" | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Malignant oral lesions | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Localization | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Differentiating features | ||
Line 631: | Line 715: | ||
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Epithelial tissue origin | * Epithelial tissue origin | ||
|Squamous cell carcinoma | | colspan="2" |Squamous cell carcinoma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 638: | Line 722: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
|Basal cell carcinoma | | colspan="2" |Basal cell carcinoma | ||
| | | | ||
| | | | ||
Line 645: | Line 729: | ||
| | | | ||
|- | |- | ||
|Verrucous crcinoma | | colspan="2" |Verrucous crcinoma | ||
| | | | ||
| | | | ||
Line 652: | Line 736: | ||
| | | | ||
|- | |- | ||
|Spindle cell carcinoma | | colspan="2" |Spindle cell carcinoma | ||
| | | | ||
| | | | ||
Line 659: | Line 743: | ||
| | | | ||
|- | |- | ||
|Adenoid squamous cell carcinoma | | colspan="2" |Adenoid squamous cell carcinoma | ||
| | | | ||
| | | | ||
Line 666: | Line 750: | ||
| | | | ||
|- | |- | ||
|Lymphoepithelioma and transitional cell carcinoma | | colspan="2" |Lymphoepithelioma and transitional cell carcinoma | ||
| | | | ||
| | | | ||
Line 673: | Line 757: | ||
| | | | ||
|- | |- | ||
|Malignant melanoma | | colspan="2" |Malignant melanoma | ||
| | | | ||
| | | | ||
Line 682: | Line 766: | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Nerve tissue origin | * Nerve tissue origin | ||
| colspan="2" |Malignant schwannoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 690: | Line 773: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | ||
* Muscle tissue origin | * Muscle tissue origin | ||
| colspan="2" |Leiomyosarcoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 701: | Line 782: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | colspan="2" |Rhabdomyosarcoma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| rowspan="7" style="background: #DCDCDC; padding: 5px; text-align: left;" | | |||
* Lymphoid tissue origin | * Lymphoid tissue origin | ||
** Plasma cell tumor | |||
** Plasma cell | |||
*** Multiple myeloma | *** Multiple myeloma | ||
*** Plasmacytoma | *** Plasmacytoma | ||
| | | colspan="2" |Malignant lymphoma | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 718: | Line 801: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | colspan="2" |Non Hodgkin lymphoma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Hodgkin lymphoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Burkitt's lymphoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Reticular cell sarcoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| rowspan="2" |Plasma cell tumor | |||
|Multiple myeloma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
|Plasmacytoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| rowspan="2" style="background: #DCDCDC; padding: 5px; text-align: left;" | | |||
* Connective and Adipose tissue origin | * Connective and Adipose tissue origin | ||
| colspan="2" |Fibrosarcoma | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 729: | Line 853: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" | | | colspan="2" |Liposarcoma | ||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| rowspan="6" style="background: #DCDCDC; padding: 5px; text-align: left;" | | |||
* Tumors of disputed origin | * Tumors of disputed origin | ||
| colspan="2" |Granular cell myoblastoma | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 743: | Line 868: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
|- | |||
| colspan="2" |Congenital epulis | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Alveolar soft part sarcoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Melanocytic neuroectodermal tumor of infancy | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Kaposi sarcoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| colspan="2" |Ewing's sarcoma | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|} | |} | ||
{| class="wikitable" | {| class="wikitable" | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Type of cancer | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Subtype | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Epidemiology | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Localization | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Clinical features | ||
! | ! style="background:#4479BA; color: #FFFFFF;" align="center" + |Diagnostic procedures | ||
|- | |- | ||
|[[Squamous cell carcinoma]] | |[[Squamous cell carcinoma]] |
Revision as of 18:43, 23 January 2019
Disease | Presentation | Risk Factors | Diagnosis | Affected Organ Systems | Important features | Picture |
---|---|---|---|---|---|---|
Diseases predominantly affecting the oral cavity | ||||||
Oral Candidiasis |
|
|
|
Localized candidiasis
Invasive candidasis |
|
|
Herpes simplex oral lesions |
|
|
|
|
||
Aphthous ulcers |
|
|
|
|
|
|
Squamous cell carcinoma |
|
|
||||
Leukoplakia |
|
|
|
|
||
Melanoma |
|
|
|
|
||
Fordyce spots |
|
|
|
|
||
Burning mouth syndrome |
|
|
||||
Torus palatinus |
|
|||||
Diseases involving oral cavity and other organ systems | ||||||
Behcet's disease |
|
|
|
|||
Crohn's disease |
|
|
|
|||
Agranulocytosis |
|
|
||||
Syphilis |
|
|
|
|||
Coxsackie virus |
|
|
||||
Chicken pox |
|
|
|
|
||
Measles |
|
|
|
|
Normal variant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
---|---|---|---|---|---|---|---|
Leukoedema | |||||||
Fordyce granules | |||||||
Benign Oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
Pyogenic granuloma | |||||||
Peripheral ossifying fibroma | |||||||
Granular cell tumor | |||||||
Peripheral giant cell granuloma | |||||||
Oral hemangioma | |||||||
Benign peripheral nerve sheath tumor | Traumatic neuroma | ||||||
Neurofibroma | |||||||
Schwannoma | |||||||
Palisaded encapsulated neuroma | |||||||
Neodymium-doped yttrium alluminium garnet | |||||||
Pigmented lesions | Diffuse | Peutz-jeghers syndrome | |||||
Addison's disease | |||||||
Heavy metal | |||||||
Drug induced | |||||||
Post inflammatory | |||||||
Smoker's melanosis | |||||||
Focal | Ephelides | ||||||
Labial melanocytic macules | |||||||
Amalgam tattoo | |||||||
Oral melanoacanthoma | |||||||
Oral melanocytic nevi | |||||||
Pre-malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
Leukoplakia | |||||||
Oral proliferative verrucous leukoplakia | |||||||
Erythroplakia | |||||||
Oral submucus fibrosis | |||||||
Oral lichen planus and lichenoid lesions | |||||||
Oral discoid lupus erythmatosus | |||||||
Oral chronic graft vs host disease | |||||||
Actinic chelitis | |||||||
Malignant oral lesions | Localization | Differentiating features | Diagnostic procedure | Treatment | |||
|
Squamous cell carcinoma | ||||||
Basal cell carcinoma | |||||||
Verrucous crcinoma | |||||||
Spindle cell carcinoma | |||||||
Adenoid squamous cell carcinoma | |||||||
Lymphoepithelioma and transitional cell carcinoma | |||||||
Malignant melanoma | |||||||
|
Malignant schwannoma | ||||||
|
Leiomyosarcoma | ||||||
Rhabdomyosarcoma | |||||||
|
Malignant lymphoma | ||||||
Non Hodgkin lymphoma | |||||||
Hodgkin lymphoma | |||||||
Burkitt's lymphoma | |||||||
Reticular cell sarcoma | |||||||
Plasma cell tumor | Multiple myeloma | ||||||
Plasmacytoma | |||||||
|
Fibrosarcoma | ||||||
Liposarcoma | |||||||
|
Granular cell myoblastoma | ||||||
Congenital epulis | |||||||
Alveolar soft part sarcoma | |||||||
Melanocytic neuroectodermal tumor of infancy | |||||||
Kaposi sarcoma | |||||||
Ewing's sarcoma |
Type of cancer | Subtype | Epidemiology | Localization | Clinical features | Diagnostic procedures |
---|---|---|---|---|---|
Squamous cell carcinoma
|
Verrucous carcinoma |
|
|
|
Biopsy shows:
Thickened club-shaped papillae and blunt stromal invaginations of well-differentiated squamous epithelium with marked keratinization |
Lymphoepithelial carcinoma | 0.8-2% of all oral or oropharyngeal cancers |
|
|
Biopsy chows:
| |
Epithelial precursor lesions | --- | --- | Seen in the entire digestive tract |
|
Biopsy shows:
|
Proliferative verrucous leukoplakia and precancerous conditions | --- |
|
|
An aggressive form of oral leukoplakia with considerable morbidity and
strong predilection to malignant transformation |
Biopsy shows:
|
Papillomas | Squamous cell papilloma and |
|
Any oral site may be affected mostly:
|
Soft, pedunculated lesions formed by a cluster of finger-like fronds or a sessile, dome-shaped lesion with a nodular, papillary or verrucous surface | Biopsy shows:
|
Condyloma acuminatum | 2nd and 5th decade with a peak in teenagers and young adults |
|
Biopsy shows:
Several sessile, cauliflower-like swellings forming a cluster | ||
Focal epithelial hyperplasia | Disease of children, adolescents and young adults |
|
|
Biopsy shows:
| |
Granular cell tumor | --- |
|
|
|
Biopsy shows:
|
Keratoacanthoma | --- |
whites
men as in women |
|
|
Biopsy shows:
|
Papillary hyperplasia | --- | Affects all age groups | Palate | Asymptomatic nodular or papillary mucosal lesion | Biopsy shows:
|
Median rhomboid glossitis | --- | --- | Dorsum of the tongue at the junction of the anterior two thirds
and posterior third |
Forms a patch of papillary atrophy in the region of the
embryological foramen caecum |
Biopsy shows:
|
Salivary gland tumors | Acinic cell carcinoma |
|
Tumors usually
form non-descript swellings |
Biopsy shows:
| |
Mucoepidermoid carcinoma |
|
|
|
Low power microscopy shows low-grade tumor with both cystic and solid areas and an inflamed, fibrous stroma | |
Adenoid cystic carcinoma |
|
|
Predominantly solid variant shows peri- and intraneural invasion | ||
Epithelial-myoepithelial
carcinoma |
--- | --- | --- | --- | |
Clear cell carcinoma,
NOS |
--- | --- | --- | ||
Basal cell | Rare in minor glands | Asymptomatic, smooth or lobulated sub-mucosal masses | Microscopically similar to basal
cell adenocarcinomas of the major gland | ||
Cystadenocarcinoma | 32% developed in the minor glands |
|
Slow growing and painless but
some palatal tumors may erode the underlying bone causing sinonasal complex |
--- | |
Salivary duct carcinoma |
|
|
Tumors formed painless swellings but many in the palate can be painful and ulcerated or fungated with metastases to regional lymph nodes | The range of
microscopical appearances is similar to that seen in the major glands | |
Salivary gland adenomas | Pleomorphic adenoma | 40-70% of minor gland tumors |
|
Painless, slow growing, submucosal masses, but when | Biopsy shows cellular, and hyaline or plasmacytoid cell |
Myoepithelioma | 42% of minor gland tumors |
|
--- | --- | |
Basal cell adenoma | 20% of minor gland tumors | --- | They are histologically
similar to those in major glands. | ||
Cystadenoma | 7% of benign minor gland tumors | --- | --- | ||
Kaposi sarcoma | --- |
|
|
Biopsy of all 4 types show:
| |
Lymphangioma | --- |
|
Tongue |
|
Biopsy shows:
|
Ectomesenchymal chondromyxoid
tumour of the anterior tongue |
--- |
|
--- | Asymptomatic, slow growing solitary nodule in the anterior dorsal tongue | Biopsy shows:
|
Focal oral mucinosis (FOM) | --- |
|
Asymptomatic fibrous or cystic-like lesion | Histopathology is characterized by:
| |
Congenital granular cell epuli | --- |
|
Solitary, somewhat pedunculated fibroma-like lesion attached to the alveolar
ridge near the midline |
||
Hematolymphoid tumors | Non-Hodgkin lymphoma | Second most common cancer of the oral cavity |
|
NHL of the lip presents with:
|
Biopsy shows:
|
Langerhans cell histiocytosis | --- |
and |
Common oral symptoms
include:
|
Biopsy shows ovoid Langerhans cells
with deeply grooved nuclei, thin nuclear membranes and abundant eosinophilic cytoplasm | |
Hodgkin lymphoma | --- |
|
Most patients present with localized disease (stage I/II), with
|
--- | |
Extramedullary myeloid
sarcoma |
--- | Isolated tumor-forming intraoral mass | Biopsy shows an Indian-file pattern of infiltration | ||
Follicular dendritic cell
sarcoma / tumour |
|
|
The patients usually
present with a painless mass |
Biopsy usually exhibits
borders and comprises:
| |
Mucosal malignant melanoma | --- |
|
80% arise:
Others:
|
|
|